Epidemiology, impact, and treatment options of restless legs syndrome in end-stage renal disease patients: An evidence-based review

Kidney International

Volumn 85, Issue 6, 2014, Pages 1275-1282

  Giannaki, Christoforos D ^a,b   Hadjigeorgiou, Georgios M ^c   Karatzaferi, Christina ^b,c   Pantzaris, Marios C ^d   Stefanidis, Ioannis ^c   Sakkas, Giorgos K ^b,c  

^a UNIVERSITY OF NICOSIA   (Cyprus)

^b INFORMATION TECHNOLOGIES INSTITUTE   (Greece)

^c UNIVERSITY OF THESSALY   (Greece)

^d CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

Author keywords

dopamine agonists; exercise; hemodialysis; quality of life; secondary RLS; sleep disorders

Indexed keywords

CLONAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; ERYTHROPOIETIN; GABAPENTIN; IRON DEXTRAN; LEVODOPA; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; TALIPEXOLE;

ABSENCE OF SIDE EFFECTS; ACTIMETRY; AEROBIC EXERCISE; BEDTIME DOSAGE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; END STAGE RENAL DISEASE; FAMILY HISTORY; HEADACHE; HEMODIALYSIS; HUMAN; INTERNATIONAL RLS STUDY GROUP QUESTIONNAIRE; KIDNEY TRANSPLANTATION; LETHARGY; MORTALITY; NAUSEA; NIGHTMARE; PATHOPHYSIOLOGY; PERIODIC LIMB MOVEMENT DISORDER; POLYSOMNOGRAPHY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RESTLESS LEGS SYNDROME; REVIEW; SKELETAL MUSCLE; SLEEP PARAMETERS; SOMNOLENCE; SYMPTOM; THERAPY EFFECT; VOMITING; WEAKNESS; WEGENER GRANULOMATOSIS; COST OF ILLNESS; EVIDENCE BASED MEDICINE; HEALTH STATUS; KIDNEY FAILURE, CHRONIC; PREDICTIVE VALUE; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME; UREMIA;

COST OF ILLNESS; DIAGNOSIS, DIFFERENTIAL; EVIDENCE-BASED MEDICINE; HEALTH STATUS; HUMANS; KIDNEY FAILURE, CHRONIC; PREDICTIVE VALUE OF TESTS; PREVALENCE; QUALITY OF LIFE; RENAL DIALYSIS; RESTLESS LEGS SYNDROME; TREATMENT OUTCOME; UREMIA;

EID: 84901932025     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.394     Document Type: Short Survey

References (52)

1. Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis 2007; 14: 82-99.
2. Giannaki CD, Sakkas GK, Karatzaferi C et al. Evidence of increased muscle atrophy and impaired quality of life parameters in patients with uremic Restless Legs Syndrome. PLoS One 2011; 6: e25180.
3. Allen RP, Picchietti D, Hening WA et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4: 101-119.
4. Schormair B, Plag J, Kaffe M et al. MEIS1 and BTBD9: genetic association with restless leg syndrome in end stage renal disease. J Med Genet 2011; 48: 462-466.
5. Zucconi M, Manconi M, Ferini Strambi L. Aetiopathogenesis of restless legs syndrome. Neurol Sci 2007; 28(SUPPL. 1): S47-S52.
6. Allen RP. Controversies and challenges in defining the etiology and pathophysiology of restless legs syndrome. Am J Med 2007; 120: S13-S21.
7. Pellecchia MT, Vitale C, Sabatini M et al. Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial vs. levodopa sustained release. Clin Neuropharmacol 2004; 27: 178-181.
8. Takaki J, Nishi T, Nangaku M et al. Clinical and psychological aspects of restless legs syndrome in uremic patients on hemodialysis. Am J Kidney Dis 2003; 41: 833-839.
9. Collado-Seidel V, Kohnen R, Samtleben W et al. Clinical and biochemical findings in uremic patients with and without restless legs syndrome. Am J Kidney Dis 1998; 31: 324-328.
10. Marconi S, Scaglione C, Pizza F et al. Group I nonreciprocal inhibition in restless legs syndrome secondary to chronic renal failure. Parkinsonism Relat Disord 2012; 18: 362-366.
11. Merlino G, Lorenzut S, Romano G et al. Restless legs syndrome in dialysis patients: a comparison between hemodialysis and continuous ambulatory peritoneal dialysis. Neurol Sci 2012; 33: 1311-1318.
12. Winkelmann J, Stautner A, Samtleben W et al. Long-term course of restless legs syndrome in dialysis patients after kidney transplantation. Mov Disord 2002; 17: 1072-1076.
13. Winkelmann J, Wetter TC, Collado-Seidel V et al. Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients. Sleep 2000; 23: 597-602.
14. Araujo SM, de Bruin VM, Nepomuceno LA et al. Restless legs syndrome in end-stage renal disease: clinical characteristics and associated comorbidities. Sleep Med 2010; 11: 785-790.
15. Giannaki CD, Sakkas GK, Hadjigeorgiou GM et al. Non-pharmacological management of periodic limb movements during hemodialysis session in patients with uremic restless legs syndrome. Asaio J 2010; 56: 538-542.
16. Winkelman JW, Chertow GM, Lazarus JM. Restless legs syndrome in endstage renal disease. Am J Kidney Dis 1996; 28: 372-378.
17. La Manna G, Pizza F, Persici E et al. Restless legs syndrome enhances cardiovascular risk and mortality in patients with end-stage kidney disease undergoing long-term haemodialysis treatment. Nephrol Dial Transplant 2011; 26: 1976-1983.
18. Siddiqui S, Kavanagh D, Traynor J et al. Risk factors for restless legs syndrome in dialysis patients. Nephron Clin Pract 2005; 101: c155-c160.
19. Unruh ML, Levey AS, D'Ambrosio C et al. Restless legs symptoms among incident dialysis patients: association with lower quality of life and shorter survival. Am J Kidney Dis 2004; 43: 900-909.
20. Jaber BL, Schiller B, Burkart JM et al. Impact of short daily hemodialysis on restless legs symptoms and sleep disturbances. Clin J Am Soc Nephrol 2011; 6: 1049-1056.
21. Chen WC, Lim PS, Wu WC et al. Sleep behavior disorders in a large cohort of chinese (Taiwanese) patients maintained by long-term hemodialysis. Am J Kidney Dis 2006; 48: 277-284.
22. Kutner NG, Zhang R, Szczech LA et al. Restless legs syndrome reported by incident haemodialysis patients: is treatment time of day relevant? Nephrology (Carlton) 2012; 17: 783-784.
23. Lin CH, Wu VC, Li WY et al. Restless legs syndrome in end-stage renal disease: a multicenter study in Taiwan. Eur J Neurol 2013; 20: 1025-1031.
24. Gigli GL, Adorati M, Dolso P et al. Restless legs syndrome in end-stage renal disease. Sleep Med 2004; 5: 309-315.
25. Walters AS, LeBrocq C, Dhar A et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003; 4: 121-132.
26. Kume A, Sato H, Nonomura H et al. An intradialysis diagnostic test for restless legs syndrome: a pilot study. Am J Kidney Dis 2009; 54: 318-326.
27. Lerma EV. Are restless legs syndrome, pruritus or hiccoughs surrogates for inadequate dialysis? Semin Dial 2011; 24: 406-407.
28. Sakkas GK, Karatzaferi C, Zintzaras E et al. Liver fat, visceral adiposity, and sleep disturbances contribute to the development of insulin resistance and glucose intolerance in nondiabetic dialysis patients. Am J Physiol Regul Integr Comp Physiol 2008; 295: R1721-R1729.
29. Enomoto M, Inoue Y, Namba K et al. Clinical characteristics of restless legs syndrome in end-stage renal failure and idiopathic RLS patients. Mov Disord 2008; 23: 811-816; quiz 926.
30. Wetter TC, Stiasny K, Kohnen R et al. Polysomnographic sleep measures in patients with uremic and idiopathic restless legs syndrome. Mov Disord 1998; 13: 820-824.
31. Allen RP, Walters AS, Montplaisir J et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005; 165: 1286-1292.
32. Gkizlis V, Giannaki CD, Karatzaferi C et al. Uremic vs. idiopathic restless legs syndrome: impact on aspects related to quality of life. Asaio J 2012; 58: 607-611.
33. Bacurau AV, Jardim MA, Ferreira JC et al. Sympathetic hyperactivity differentially affects skeletal muscle mass in developing heart failure: role of exercise training. J Appl Physiol 2009; 106: 1631-1640.
34. Lindner A, Fornadi K, Lazar AS et al. Periodic limb movements in sleep are associated with stroke and cardiovascular risk factors in patients with renal failure. J Sleep Res 2012; 21: 297-307.
35. Portaluppi F, Cortelli P, Buonaura GC et al. Do restless legs syndrome (RLS) and periodic limb movements of sleep (PLMS) play a role in nocturnal hypertension and increased cardiovascular risk of renally impaired patients? Chronobiol Int 2009; 26: 1206-1221.
36. Li Y, Walters AS, Chiuve SE et al. Prospective study of restless legs syndrome and coronary heart disease among women. Circulation 2012; 126: 1689-1694.
37. Schlesinger I, Erikh I, Avizohar O et al. Cardiovascular risk factors in restless legs syndrome. Mov Disord 2009; 24: 1587-1592.
38. Pennestri MH, Montplaisir J, Fradette L et al. Blood pressure changes associated with periodic leg movements during sleep in healthy subjects. Sleep Med 2013; 14: 555-561.
39. Giannaki CD, Zigoulis P, Karatzaferi C et al. Periodic limb movements in sleep contribute to further cardiac structure abnormalities in hemodialysis patients with restless legs syndrome. J Clin Sleep Med 2013; 9: 147-153.
40. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9: S16-S23.
41. Benz RL, Pressman MR, Hovick ET et al. Potential novel predictors of mortality in end-stage renal disease patients with sleep disorders. Am J Kidney Dis 2000; 35: 1052-1060.
42. Trenkwalder C, Stiasny K, Pollmacher T et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep 1995; 18: 681-688.
43. Giannaki CD, Sakkas GK, Karatzaferi C et al. Effect of exercise training and dopamine agonists in patients with uremic restless legs syndrome: a sixmonth randomized, partially double-blind, placebo-controlled comparative study. BMC Nephrol 2013; 14: 194.
44. Miranda M, Kagi M, Fabres L et al. Pramipexole for the treatment of uremic restless legs in patients undergoing hemodialysis. Neurology 2004; 62: 831-832.
45. Pieta J, Millar T, Zacharias J et al. Effect of pergolide on restless legs and leg movements in sleep in uremic patients. Sleep 1998; 21: 617-622.
46. Thorp ML, Morris CD, Bagby SP. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001; 38: 104-108.
47. Micozkadioglu H, Ozdemir FN, Kut A et al. Gabapentin vs. levodopa for the treatment of Restless Legs Syndrome in hemodialysis patients: an open-label study. Ren Fail 2004; 26: 393-397.
48. Sloand JA, Shelly MA, Feigin A et al. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004; 43: 663-670.
49. Benz RL, Pressman MR, Hovick ET et al. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study). Am J Kidney Dis 1999; 34: 1089-1095.
50. Sakkas GK, Hadjigeorgiou GM, Karatzaferi C et al. Intradialytic aerobic exercise training ameliorates symptoms of restless legs syndrome and improves functional capacity in patients on hemodialysis: a pilot study. Asaio J 2008; 54: 185-190.
51. Giannaki CD, Hadjigeorgiou GM, Karatzaferi C et al. A single-blind randomized controlled trial to evaluate the effect of 6 months progressive aerobic exercise training in patients with uraemic restless legs syndrome. Nephrol Dial Transplant; e-pub ahead of print 8 August 2013.
52. Bronas UG. Exercise training and reduction of cardiovascular disease risk factors in patients with chronic kidney disease. Adv Chronic Kidney Dis 2009; 16: 449-458.